These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 24379203

  • 1. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
    Robillard KR, Chan GN, Zhang G, la Porte C, Cameron W, Bendayan R.
    Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
    [Abstract] [Full Text] [Related]

  • 2. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [Abstract] [Full Text] [Related]

  • 3. Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.
    Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, Mabondzo A.
    AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1147-54. PubMed ID: 18729774
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C, Barrail A, Goujard C, Taburet AM.
    Clin Pharmacokinet; 2005 Sep; 44(10):1035-50. PubMed ID: 16176117
    [Abstract] [Full Text] [Related]

  • 5. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [Abstract] [Full Text] [Related]

  • 6. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R, Agarwal S, Mittapalli RK, Elmquist WF.
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [Abstract] [Full Text] [Related]

  • 7. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [Abstract] [Full Text] [Related]

  • 8. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
    Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ.
    J Antimicrob Chemother; 2010 Aug; 65(8):1672-80. PubMed ID: 20551216
    [Abstract] [Full Text] [Related]

  • 9. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.
    Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R.
    Pharm Res; 2013 Apr; 30(4):1050-64. PubMed ID: 23224979
    [Abstract] [Full Text] [Related]

  • 10. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N.
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
    Mallolas J, Sarasa M, Nomdedeu M, Soriano A, López-Púa Y, Blanco JL, Martínez E, Gatell JM.
    HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
    [Abstract] [Full Text] [Related]

  • 12. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.
    Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, Bendayan R.
    J Neurosci Res; 2009 Mar; 87(4):1023-36. PubMed ID: 18855943
    [Abstract] [Full Text] [Related]

  • 13. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S, Sane R, Ohlfest JR, Elmquist WF.
    J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
    [Abstract] [Full Text] [Related]

  • 14. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED.
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O.
    Clin Cancer Res; 2007 Nov 01; 13(21):6440-9. PubMed ID: 17975156
    [Abstract] [Full Text] [Related]

  • 16. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
    Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, Agarwala S, Dragone J, Bertz R.
    J Clin Pharmacol; 2011 Mar 01; 51(3):368-77. PubMed ID: 20457590
    [Abstract] [Full Text] [Related]

  • 17. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.
    Antivir Ther; 2007 Mar 01; 12(5):825-30. PubMed ID: 17713166
    [Abstract] [Full Text] [Related]

  • 18. Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.
    Mishra T, Shrivastav PS.
    ScientificWorldJournal; 2014 Mar 01; 2014():482693. PubMed ID: 24587725
    [Abstract] [Full Text] [Related]

  • 19. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.
    Mol Cancer Ther; 2008 Aug 01; 7(8):2280-7. PubMed ID: 18723475
    [Abstract] [Full Text] [Related]

  • 20. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2010 Jun 01; 333(3):788-96. PubMed ID: 20304939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.